| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | gp130 |
| Uniprot No | P42704 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1221-1394aa |
| 氨基酸序列 | LFRKVIEEQLEPAVEKISIMAERLANQFAIYKPVTDFFLQLVDAGKVDDARALLQRCGAIAEQTPILLLFLLRNSRKQGKASTVKSVLELIPELNEKEEAYNSLMKSYVSEKDVTSAKALYEHLTAKNTKLDDLFLKRYASLLKYAGEPVPFIEPPESFEFYAQQLRKLRENSS |
| 预测分子量 | 26.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于gp130重组蛋白的3篇代表性文献的简要信息(注：文献为示例性概括，非真实引用)：
---
1. **文献名称**：*Structure-function analysis of the gp130 receptor subunit*
**作者**：Heinrich PC, et al.
**摘要**：本研究解析了重组gp130蛋白的胞外结构域，揭示了其与IL-6/IL-6Rα复合物的结合机制，阐明了gp130在启动JAK/STAT信号通路中的关键构象变化。
2. **文献名称**：*Soluble gp130 as an inhibitor of IL-6 trans-signaling in inflammatory disease models*
**作者**：Rose-John S, et al.
**摘要**：报道了一种可溶性重组gp130蛋白的设计与应用，通过阻断IL-6的跨信号传递(trans-signaling)，显著减轻了小鼠结肠炎模型的炎症反应，为靶向治疗提供了新策略。
3. **文献名称**：*Recombinant gp130 protein enhances cardiomyocyte survival via STAT3 activation*
**作者**：Hirota H, et al.
**摘要**：实验证明重组gp130蛋白通过激活STAT3信号通路，促进缺氧条件下心肌细胞的存活，提示其在心脏缺血性疾病中的潜在治疗价值。
---
**注**：以上内容为领域研究方向示例，具体文献需通过PubMed或Web of Science等数据库检索确认。如需实际文献，建议使用关键词“gp130 recombinant protein”或“gp130 signaling”进行查询。
gp130. also known as glycoprotein 130 or IL6ST (Interleukin-6 Signal Transducer), is a shared transmembrane receptor component critical for signaling pathways of the interleukin-6 (IL-6) cytokine family. Discovered in the early 1990s, gp130 does not bind ligands directly but serves as a signal-transducing β-subunit that partners with ligand-specific α-receptors (e.g., IL-6Rα, LIFR) to form functional receptor complexes. This modular design allows gp130 to mediate diverse cellular responses, including inflammation, immune regulation, cell survival, and differentiation, by interacting with cytokines such as IL-6. IL-11. leukemia inhibitory factor (LIF), and ciliary neurotrophic factor (CNTF).
Recombinant gp130 proteins are engineered versions produced via genetic modification in expression systems like mammalian cells, bacteria, or insect cells. These proteins typically retain extracellular domains necessary for binding to ligand-receptor complexes or act as soluble decoys to modulate signaling. Researchers use recombinant gp130 to study its role in JAK-STAT, MAPK, and PI3K-Akt signaling pathways, which are implicated in autoimmune diseases, cancer, and metabolic disorders. For example, soluble gp130-Fc fusion proteins can inhibit IL-6 trans-signaling, a pro-inflammatory mechanism linked to chronic inflammation and tumor progression.
Clinically, gp130-targeted therapies are being explored to treat conditions like rheumatoid arthritis and cytokine release syndrome. However, challenges persist due to the pleiotropic functions of gp130 in homeostasis and pathology. Recombinant gp130 tools remain vital for dissecting its complex biology and developing precision therapies that balance therapeutic efficacy with minimal off-target effects. Advances in structural biology and protein engineering continue to refine these molecules for research and translational applications.
×
